Cargando…

Protection against invasive meningococcal disease and vaccination policy in the Netherlands

BACKGROUND: A rise in serogroup C invasive meningococcal disease (IMD-C) led to introduction of MenC vaccination in 2002 in the Netherlands at 14 months of age, accompanied by a mass-campaign for all children between 1 and 18 years (coverage 94%). Due to an IMD-W outbreak in 2016-17, the MenC vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohm, M, Knol, M, Sanders, E, Berbers, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593912/
http://dx.doi.org/10.1093/eurpub/ckac130.098
_version_ 1784815280927539200
author Ohm, M
Knol, M
Sanders, E
Berbers, G
author_facet Ohm, M
Knol, M
Sanders, E
Berbers, G
author_sort Ohm, M
collection PubMed
description BACKGROUND: A rise in serogroup C invasive meningococcal disease (IMD-C) led to introduction of MenC vaccination in 2002 in the Netherlands at 14 months of age, accompanied by a mass-campaign for all children between 1 and 18 years (coverage 94%). Due to an IMD-W outbreak in 2016-17, the MenC vaccine was replaced by a MenACWY vaccine and an adolescent booster at 14 years was introduced next to a mass campaign for 14-18 year-olds in 2018. AIM/METHODS: We explored meningococcal antibody status in the Netherlands across the population in 2006-07, 2016-17 and 2020 in consecutive cross-sectional serosurveillance studies. Furthermore, we assessed the vaccine impact and effectiveness of the recent MenACWY vaccination campaign. We determined long-term protection in both adolescents and adults after a MenACWY vaccination and investigated sex-related differences in the vaccine response in adolescents. RESULTS: MenC antibody levels were low in 2016-17, except in recently vaccinated toddlers and individuals who were vaccinated as teenagers in 2002. We demonstrated waning of MenC immunity 15 years after the mass campaign and highlighted the lack of meningococcal AWY immunity across the population, which underlined the importance of the recently introduced MenACWY (booster) vaccination. The MenACWY vaccination program was effective in preventing IMD-W in the target population. Long-term protection was achieved for MenC, MenW, and MenY in 94-96% of adolescents five years postvaccination, but in adults only in 32%, 65% and 71% for MenC, W and Y. Adolescent antibody responses were higher in girls than in boys for all serogroups at most timepoints after MenACWY vaccination. The differences in average titers were however small and the percentage of participants with protective titers was very high for both sexes. CONCLUSIONS: The current meningococcal vaccination policy in the Netherlands provides protection across the population against IMD-ACWY and seems sufficient on the long-term. KEY MESSAGES: The current meningococcal vaccination policy in the Netherlands provides protection across the population against IMD-ACWY and seems sufficient on the long-term. The current meningococcal vaccination policy in the Netherlands provides protection across the population against IMD-ACWY and seems sufficient on the long-term.
format Online
Article
Text
id pubmed-9593912
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95939122022-11-22 Protection against invasive meningococcal disease and vaccination policy in the Netherlands Ohm, M Knol, M Sanders, E Berbers, G Eur J Public Health Poster Walks BACKGROUND: A rise in serogroup C invasive meningococcal disease (IMD-C) led to introduction of MenC vaccination in 2002 in the Netherlands at 14 months of age, accompanied by a mass-campaign for all children between 1 and 18 years (coverage 94%). Due to an IMD-W outbreak in 2016-17, the MenC vaccine was replaced by a MenACWY vaccine and an adolescent booster at 14 years was introduced next to a mass campaign for 14-18 year-olds in 2018. AIM/METHODS: We explored meningococcal antibody status in the Netherlands across the population in 2006-07, 2016-17 and 2020 in consecutive cross-sectional serosurveillance studies. Furthermore, we assessed the vaccine impact and effectiveness of the recent MenACWY vaccination campaign. We determined long-term protection in both adolescents and adults after a MenACWY vaccination and investigated sex-related differences in the vaccine response in adolescents. RESULTS: MenC antibody levels were low in 2016-17, except in recently vaccinated toddlers and individuals who were vaccinated as teenagers in 2002. We demonstrated waning of MenC immunity 15 years after the mass campaign and highlighted the lack of meningococcal AWY immunity across the population, which underlined the importance of the recently introduced MenACWY (booster) vaccination. The MenACWY vaccination program was effective in preventing IMD-W in the target population. Long-term protection was achieved for MenC, MenW, and MenY in 94-96% of adolescents five years postvaccination, but in adults only in 32%, 65% and 71% for MenC, W and Y. Adolescent antibody responses were higher in girls than in boys for all serogroups at most timepoints after MenACWY vaccination. The differences in average titers were however small and the percentage of participants with protective titers was very high for both sexes. CONCLUSIONS: The current meningococcal vaccination policy in the Netherlands provides protection across the population against IMD-ACWY and seems sufficient on the long-term. KEY MESSAGES: The current meningococcal vaccination policy in the Netherlands provides protection across the population against IMD-ACWY and seems sufficient on the long-term. The current meningococcal vaccination policy in the Netherlands provides protection across the population against IMD-ACWY and seems sufficient on the long-term. Oxford University Press 2022-10-25 /pmc/articles/PMC9593912/ http://dx.doi.org/10.1093/eurpub/ckac130.098 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Walks
Ohm, M
Knol, M
Sanders, E
Berbers, G
Protection against invasive meningococcal disease and vaccination policy in the Netherlands
title Protection against invasive meningococcal disease and vaccination policy in the Netherlands
title_full Protection against invasive meningococcal disease and vaccination policy in the Netherlands
title_fullStr Protection against invasive meningococcal disease and vaccination policy in the Netherlands
title_full_unstemmed Protection against invasive meningococcal disease and vaccination policy in the Netherlands
title_short Protection against invasive meningococcal disease and vaccination policy in the Netherlands
title_sort protection against invasive meningococcal disease and vaccination policy in the netherlands
topic Poster Walks
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593912/
http://dx.doi.org/10.1093/eurpub/ckac130.098
work_keys_str_mv AT ohmm protectionagainstinvasivemeningococcaldiseaseandvaccinationpolicyinthenetherlands
AT knolm protectionagainstinvasivemeningococcaldiseaseandvaccinationpolicyinthenetherlands
AT sanderse protectionagainstinvasivemeningococcaldiseaseandvaccinationpolicyinthenetherlands
AT berbersg protectionagainstinvasivemeningococcaldiseaseandvaccinationpolicyinthenetherlands